Related Experiment Video
Updated: Jan 25, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
Published on: January 6, 2023
Advancements in targeted therapies for acute myeloid leukemia
Matthew P Connor1, Adam Barsouk1, Omar Elghawy1
1University of Pennsylvania, Department of Medicine, Division of Hematology and Oncology, 3400 Civic Center Blvd, 12 South Pavilion, Philadelphia, PA 19104, USA.
Abstract:
For decades, the only therapeutic option for acute myeloid leukemia (AML) had been intensive combination chemotherapy. In recent years, understanding of the molecular mechanisms underlying myeloid oncogenesis has grown immensely and has led to the development of multiple effective small molecule inhibitors of aberrant cellular signaling. This review highlights the major AML mutational pathways currently being targeted with precision therapies: the receptor tyrosine kinase FLT3, the citric acid cycle enzymes IDH1 and IDH2, and the transcription-regulating KMT2A and NPM1 genes. We review the major clinical trials evaluating the safety and efficacy of agents targeting these pathways, as well as ongoing and upcoming studies of novel and combination therapies for these molecular subsets of AML.
Insights
Precision therapies targeting specific mutations like FLT3, IDH1/IDH2, KMT2A, and NPM1 are revolutionizing acute myeloid leukemia (AML) treatment beyond traditional chemotherapy.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) treatment historically relied on intensive chemotherapy.
- Recent advances in understanding oncogenesis have enabled targeted therapies.
Purpose of the Study:
- To review precision therapies targeting key AML mutational pathways.
- To summarize clinical trials and future directions for targeted AML treatments.
Main Methods:
- Review of major clinical trials for FLT3, IDH1/IDH2, KMT2A, and NPM1 inhibitors.
- Analysis of safety and efficacy data for targeted agents.
- Discussion of ongoing and upcoming combination therapies.
Main Results:
- Small molecule inhibitors targeting FLT3, IDH1/IDH2, KMT2A, and NPM1 show efficacy.
- Precision therapies offer new options for molecular subsets of AML.
- Combination strategies are being explored for enhanced outcomes.
Conclusions:
- Targeted therapies represent a significant advancement in AML treatment.
- Further research into novel and combination therapies is crucial for improving patient outcomes.
- Personalized medicine approaches are transforming AML management.
More Related Videos
06:33Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Gene Therapy
Extraction: Advanced Methods
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Group Therapy
Differentiation of Common Myeloid Progenitor Cells